4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Poxel S.A. (POXEL) operates in the Biotechnology industry and is headquartered in Lyon, France with about 5 employees. Its market capitalization is roughly €13 million.
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction.
Interactive charts & full statements →
| Income statement | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | — | €2M | €1M | €13M |
| Gross Profit | — | €0M | €0M | €13M |
| Operating Income (EBIT) | — | (€29M) | (€22M) | (€22M) |
| Net Income | — | (€35M) | (€31M) | (€24M) |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Total Assets | €5M | €35M | €55M |
| Total Liabilities | €54M | €53M | €47M |
EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive POXEL viewer.
About TickerBase · Data methodology & sources · Privacy · Terms